Effects of Tysabri Over 12 Months on MS Related Fatigue in Patients With RRMS (TYNERGY)

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: April 17, 2009
Last updated: November 3, 2011
Last verified: November 2011

Fatigue is a problem in 75-95% of MS patients and many report fatigue as one of their most disabling symptoms which contributes to cognitive and physical difficulties. Treatment that can decrease fatigue will improve the quality of life for this group of patients. Small studies and anecdotal reports have suggested that TYSABRI as opposed to other disease modifying therapies can decrease fatigue in MS patients. Data from a more substantial trial population and a well-defined fatigue scale is warranted to verify these observations.

Condition Intervention Phase
Relapsing Remitting Multiple Sclerosis
Other: tests and questionnaires
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • To investigate the MS related fatigue during treatment with TYSABRI as measured by changes in the fatigue scale for motor and cognitive functions (FMSC) over the course of 12 months. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in fatigue, capacity for work, HRQoL, sleepiness, cognitive impairment, physical activity induced exhaustion, speed of walking, status of MS disease progression and amount of walking at different time points after initiation of TYSABRI treatment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • To investigate correlation between fatigue and cognitive impairment, depression and physically activity induced exhaustion and status of MS disease progression [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • To document any changes in fatigue related medication [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 200
Study Start Date: April 2009
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Tests and questionnaires
Measuring MS related fatigue over the first 12 months following initiation of treatment with TYSABRI
Other: tests and questionnaires
measuring fatigue, capacity for work, health related quality of life, sleepiness, depression, cognitive impairment, physical activity induced exhaustion, speed od walking, status of MS disease progression and amount of walking.
Other Names:
  • 6MWT
  • BS-CR10
  • CES-D
  • CWQ
  • EDSS
  • ESS
  • FSMC
  • SDMT
  • SF-12


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 and < 65 at screening
  • TYSABRI prescribed according to national guidelines but not yet started treatment
  • Signed informed consent form
  • FSMC sum score above 43 at baseline (mild fatigue)

Exclusion Criteria:

  • FSMC sum score below 43 at baseline
  • History of treatment with TYSABRI
  • EDSS > 6 at baseline
  • Amphetamine as medication
  • Major depression
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00884481

Norrlands Universitets Sjukhus
Umeå, Sweden, 90185
Sponsors and Collaborators
  More Information

No publications provided by Biogen

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr Anders Svenningsson, Norrlands University Hospital
ClinicalTrials.gov Identifier: NCT00884481     History of Changes
Obsolete Identifiers: NCT00966797
Other Study ID Numbers: 2008-008065-35
Study First Received: April 17, 2009
Last Updated: November 3, 2011
Health Authority: Sweden: Regional Ethical Review Board

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Signs and Symptoms

ClinicalTrials.gov processed this record on July 05, 2015